Answers are grounded in this paper and cite their sources.
BACKGROUND: The role of specialist palliative care (SPC) alongside immunotherapy in head and neck cancer (HNC) is unclear. METHODS: This retrospective population-based cohort study included adults with HNC who died in 2013-2021 in Alberta, Canada. The primary exposure was SPC timing (early, late, none), with immunotherapy use in the last 12 months of life as a secondary exposure. The outcome was potentially avoidable acute care use (ICU admission, 15+ hospital days, or 2+ ED visits) in the last month of life. Multivariable logistic regression was performed. RESULTS: Of 1415 patients, 35.3%, 36.7%, and 28.0% received early, late, and no SPC, respectively, while 6.9% received immunotherapy. Early SPC was associated with 40% (95% CI 17%-57%) lower odds of potentially avoidable acute care use, while immunotherapy use was not associated with this outcome (p-value = 0.91). CONCLUSION: Early SPC was associated with lower potentially avoidable acute care use for HNC regardless of immunotherapy use.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: